Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA.
Zhang J, et al. Among authors: van der gang lf.
J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641-8. doi: 10.1016/j.jaad.2024.04.026. Online ahead of print.
J Am Acad Dermatol. 2024.
PMID: 38653344